Brenton G. Mar
0000-0002-3857-9324
Publication & Citation Trends
Publications
0 total
Abstract LB123: Poorer outcomes in EGFR L858R-driven NSCLC treated with osimertinib may be addressed with novel combination of BLU-945 and osimertinib
Cited by 0
Semantic Scholar
Integration of genomic sequencing drives therapeutic targeting of PDGFRA in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. OA
Cited by 4
Semantic Scholar
Avapritinib versus Placebo in Indolent Systemic Mastocytosis. OA
Cited by 48
Semantic Scholar
Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF©) and determination of a threshold score for moderate symptoms OA
Cited by 4
Semantic Scholar
MA07.03 Real-world Landscape of EGFR C797X Mutation as a Resistance Mechanism to Osimertinib in Non-small Cell Lung Cancer
Cited by 8
Semantic Scholar
Whole exome sequencing of a breast tumor in a patient with Diamond Blackfan anemia.
Cited by 0
Semantic Scholar
Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF). OA
Cited by 6
Semantic Scholar
Abstract CT023: PATHFINDER: Interim analysis of avapritinib (ava) in patients (pts) with advanced systemic mastocytosis (AdvSM)
Cited by 2
Semantic Scholar
Research Topics
PI3K/AKT/mTOR signaling in cancer
(49)
Lung Cancer Treatments and Mutations
(33)
Acute Myeloid Leukemia Research
(26)
Acute Lymphoblastic Leukemia research
(26)
Mast cells and histamine
(18)
Affiliations
Broad Institute
Boston University
Otsuka (Japan)
Brigham and Women's Hospital
Novartis (Switzerland)